Metastatic Bone Disease Treatment Market Size is expected to record a substantial CAGR between 2022 and 2028. MBD (metastatic bone disease) primarily originates in one area of the body, such as a tissue, gland, or organ, and then spreads to bone. According to statistics, around 50% of cancers that begin in an organ can spread to the skeleton.
However, increasing advancements in the medical treatment of numerous cancers, particularly prostate, lung, and breast, are helping in enhancing the life of patients. As per experts, it is advisable for every cancer patient to discuss the risk of developing MBD with an oncologist.
Based on cancer type, the osteoblastic bone metastasis segment is set to observe considerable proceeds in the metastasis bone disease treatment market through 2028. This rise can be credited to the increasing incidence of the disease, which leads to the formation of excess cells and makes bones very dense.
The condition often occurs with metastatic prostate cancer and can be treated via a combination of methods. According to the Canadian Cancer Society, these methods include pain medications, radiation therapy, chemotherapy, denosumab, bisphosphonate medications, and others.
On the basis of end-use, the metastatic bone disease treatment market is estimated to witness lucrative growth from the hospitals segment owing to the requirement of cutting-edge healthcare infrastructure for the effective management of metastatic cancer. The segmental expansion is attributed to the availability of favorable reimbursement facilities and the provision of quality of care services in hospitals.
Considering the regional perspective, the North America metastatic bone disease treatment market size is expected to depict appreciable CAGR through 2028 with an increase in regulatory approvals. For instance, in December 2021, Zetagen Therapeutics secured the approval of the FDA for its ZetaMet cancer treatment technology. The device is equipped with a small-molecule, synthetic, and inductive biologic technology for resolving and targeting metastatic bone lesions.
Major companies across the metastatic bone disease treatment market comprise Merck, Bayer, F. Hoffmann-La Roche, Novartis, Eli Lilly and Company, C. R. Bard, Boston Scientific Corporation, Fresenius Kabi, Medtronic, and others. These players are focusing on the adoption of strategic initiatives such as collaborations, partnerships, product developments, mergers, and acquisitions for consolidating their position in the market.
A few instances of the same are as follows:
The SARS-CoV-2 pandemic has created new challenges in the optimum management of patients diagnosed with cancer. This has led hospital authorities, clinicians, as well as patients to balance the risks of attending hospitals, given that most patients are particularly vulnerable, with the risks of modifying or delaying cancer treatment.
Further studies indicate that COVID-19 had a substantial impact on the management of metastatic bone disease in cancer treatment induced bone loss, adjuvant bisphosphonate breast cancer therapy, and all solid tumor types and myeloma. These factors have opened avenues for product innovations in the field of metastatic bone disease diagnosis and treatment for enhancing patient satisfaction.
Market, By Treatment
Market, By Origin of Metastasis
Market, By End-user
The above information is provided for the following regions and countries: